United Therapeutics Corporation
https://www.unither.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From United Therapeutics Corporation
Deal Watch: Organon Obtains Rights To Perjeta, Prolia/Xgeva Biosimilars From Shanghai Henlius
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
Juicy Apples Come From Healthy Trees: Advice For Platform Developers
Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.
Almirall Throws Down Gauntlet To Dupixent With New Lebrikizumab Data
The Spanish group has revealed that eight out of ten atopic dermatitis patients treated with lebrikizumab maintained skin clearance after a year, which compares favorably with Sanofi and Regeneron's blockbuster Dupixent.
Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Lung Biotechnology PBC
- Lung Rx, Inc.
- SteadyMed Ltd.
- SteadyMed Therapeutics, Inc.
- Unither Pharmaceuticals
- Unither Virology